Cefditoren
- Generic Name
- Cefditoren
- Brand Names
- Spectracef
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18N6O5S3
- CAS Number
- 104145-95-1
- Unique Ingredient Identifier
- 81QS09V3YW
- Background
Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.
- Indication
For the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of microorganisms in acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, pharyngitis/tonsillitis, and uncomplicated skin and skin-structure infections.
- Associated Conditions
- Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB), Bacterial Infections, Community Acquired Pneumonia (CAP), Streptococcal Pharyngitis, Tonsillitis streptococcal, Uncomplicated skin and subcutaneous tissue bacterial infections
Pharmacokinetic Study of Cefditoren Pivoxil in Breast Milk and Blood of Lactating Women
- Conditions
- Medication SafetyDrug SafetyDrug Metabolism
- Interventions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- West China Second University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT06644105
- Locations
- 🇨🇳
West China Second University Hospital, Chengdu, China
Pilot Study of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Meiji Pharma Spain S.A.
- Target Recruit Count
- 20
- Registration Number
- NCT04709172
- Locations
- 🇪🇸
HU Henares, Coslada, Madrid, Spain
Study of Cefditoren Pivoxil in Treatment of Childhood With Acute Rhinosinusitis
- First Posted Date
- 2012-03-13
- Last Posted Date
- 2012-03-14
- Lead Sponsor
- Thammasat University
- Target Recruit Count
- 120
- Registration Number
- NCT01553006
- Locations
- 🇹ðŸ‡
Thammasat University, Prathumthani, Thailand
Efficacy and Safety of Cefditoren Pivoxil Versus Ciprofloxacin in Acute Uncomplicated Cystitis
- Conditions
- Urinary Tract Infections
- Interventions
- First Posted Date
- 2008-01-21
- Last Posted Date
- 2010-06-29
- Lead Sponsor
- Tedec-Meiji Farma, S.A.
- Target Recruit Count
- 611
- Registration Number
- NCT00598403
- Locations
- 🇪🇸
CAP Remei, Vic, Barcelona, Spain
🇪🇸CAP Florida Nord, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸CS Basurto, Bilbao, Vizcaya, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.